PERIPHERAL BLOOD BIOMARKERS DYNAMICS PREDICT CLINICAL RESPONSE TO PEMBROLIZUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS METASTATIC NON-SMALL CELL LUNG CANCER